136 related articles for article (PubMed ID: 24039150)
1. X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors.
Xue Y; Wan PT; Hillertz P; Schweikart F; Zhao Y; Wissler L; Dekker N
ChemMedChem; 2013 Nov; 8(11):1846-54. PubMed ID: 24039150
[TBL] [Abstract][Full Text] [Related]
2. The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor.
Kiefer SE; Chang CJ; Kimura SR; Gao M; Xie D; Zhang Y; Zhang G; Gill MB; Mastalerz H; Thompson LA; Cacace AM; Sheriff S
Acta Crystallogr F Struct Biol Commun; 2014 Feb; 70(Pt 2):173-81. PubMed ID: 24637750
[TBL] [Abstract][Full Text] [Related]
3. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.
Sato S; Cerny RL; Buescher JL; Ikezu T
J Neurochem; 2006 Sep; 98(5):1573-84. PubMed ID: 16923168
[TBL] [Abstract][Full Text] [Related]
4. Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites.
Dillon GM; Henderson JL; Bao C; Joyce JA; Calhoun M; Amaral B; King KW; Bajrami B; Rabah D
PLoS One; 2020; 15(4):e0228771. PubMed ID: 32255788
[TBL] [Abstract][Full Text] [Related]
5. Identification of tau-tubulin kinase 1 inhibitors by microfluidics-based mobility shift assay from a kinase inhibitor library.
Wang J; Lin Y; Xu X; Wang Y; Xie Q
SLAS Discov; 2023 Dec; 28(8):385-393. PubMed ID: 37399991
[TBL] [Abstract][Full Text] [Related]
6. The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor.
Marcotte DJ; Spilker KA; Wen D; Hesson T; Patterson TA; Kumar PR; Chodaparambil JV
Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):103-108. PubMed ID: 32133995
[TBL] [Abstract][Full Text] [Related]
7. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
8. Selection of fragments for kinase inhibitor design: decoration is key.
Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors.
Tari LW; Hoffman ID; Bensen DC; Hunter MJ; Nix J; Nelson KJ; McRee DE; Swanson RV
Bioorg Med Chem Lett; 2007 Feb; 17(3):688-91. PubMed ID: 17157005
[TBL] [Abstract][Full Text] [Related]
10. Development of novel molecular probes of the Rio1 atypical protein kinase.
Mielecki M; Krawiec K; Kiburu I; Grzelak K; Zagórski W; Kierdaszuk B; Kowa K; Fokt I; Szymanski S; Swierk P; Szeja W; Priebe W; Lesyng B; LaRonde-LeBlanc N
Biochim Biophys Acta; 2013 Jul; 1834(7):1292-301. PubMed ID: 23523885
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Regulation and Diverse Activities of Tau-Tubulin Kinase (TTBK) Isoforms.
Bao C; Bajrami B; Marcotte DJ; Chodaparambil JV; Kerns HM; Henderson J; Wei R; Gao B; Dillon GM
Cell Mol Neurobiol; 2021 May; 41(4):669-685. PubMed ID: 32424773
[TBL] [Abstract][Full Text] [Related]
12. The structural, functional, and dynamic effect of Tau tubulin kinase1 upon a mutation: A neuro-degenerative hotspot.
Ahamad S; Hema K; Kumar V; Gupta D
J Cell Biochem; 2021 Nov; 122(11):1653-1664. PubMed ID: 34297427
[TBL] [Abstract][Full Text] [Related]
13. Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.
Nozal V; Martinez A
Eur J Med Chem; 2019 Jan; 161():39-47. PubMed ID: 30342424
[TBL] [Abstract][Full Text] [Related]
14. Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation.
Jana S; Singh SK
J Biomol Struct Dyn; 2020 Feb; 38(3):886-900. PubMed ID: 30829560
[TBL] [Abstract][Full Text] [Related]
15. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
16. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
Elling RA; Fucini RV; Romanowski MJ
Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
[TBL] [Abstract][Full Text] [Related]
17. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
[TBL] [Abstract][Full Text] [Related]
18. Compounds binding to the S2-S3 pockets of thrombin.
Nilsson M; Hämäläinen M; Ivarsson M; Gottfries J; Xue Y; Hansson S; Isaksson R; Fex T
J Med Chem; 2009 May; 52(9):2708-15. PubMed ID: 19371038
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide-induced conformational changes in the Saccharomyces cerevisiae SR protein kinase, Sky1p, revealed by X-ray crystallography.
Nolen B; Ngo J; Chakrabarti S; Vu D; Adams JA; Ghosh G
Biochemistry; 2003 Aug; 42(32):9575-85. PubMed ID: 12911299
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
